RXDX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 3.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Prometheus Biosciences Insider Trading History Chart

Prometheus Biosciences Share Price & Price History

^$199.92

▲ +0.18 (0.09%)

As of 06/16/2023 09:00 PM ET

The A.I. story nobody is telling you (Read ASAP)

From TradeSmith | Ad

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Prometheus Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/5/2023	Keith W Marshall	CFO	Sell	10,000	$108.42	$1,084,200.00	9,811
3/15/2023	Mark C Mckenna	CEO	Sell	25,000	$116.14	$2,903,500.00	55,144
3/8/2023	Sinai Intellectual Prop Cedars	Major Shareholder	Sell	865,000	$114.59	$99,120,350.00	4,001,132
3/6/2023	Keith W Marshall	CFO	Sell	10,000	$122.13	$1,221,300.00	9,811
3/3/2023	Mark C Mckenna	CEO	Sell	10,620	$125.13	$1,328,880.60	55,144
3/1/2023	Mark C Mckenna	CEO	Sell	700	$125.26	$87,682.00	55,144
2/16/2023	Mark C Mckenna	CEO	Sell	25,000	$119.87	$2,996,750.00	55,144
2/15/2023	Keith W Marshall	CFO	Sell	5,000	$119.38	$596,900.00	9,811
1/17/2023	Keith W Marshall	CFO	Sell	5,000	$119.00	$595,000.00	9,811
1/17/2023	Mark C Mckenna	CEO	Sell	25,000	$118.99	$2,974,750.00	55,144

The A.I. story nobody is telling you (Read ASAP)

From TradeSmith | Ad

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

SEC Filings (Institutional Ownership Changes) for Prometheus Biosciences (NASDAQ:RXDX)

92.66% of Prometheus Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Prometheus Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
6/1/2023	Prelude Capital Management LLC	7,200	$0.77M	0.0%	+200.0%	0.015%
5/26/2023	ProShare Advisors LLC	7,391	$0.79M	0.0%	-7.0%	0.015%
5/25/2023	Legato Capital Management LLC	8,074	$0.87M	0.2%	-16.2%	0.017%
5/16/2023	Fred Alger Management LLC	1,331,759	$142.92M	0.8%	-2.0%	2.786%
5/15/2023	Affinity Asset Advisors LLC	150,000	$16.10M	5.3%	+100.0%	0.314%
5/15/2023	Moore Capital Management LP	20,381	$2.19M	0.0%	N/A	0.043%
5/15/2023	RTW Investments LP	3,272,104	$351.16M	7.3%	-2.5%	6.884%
5/15/2023	Ghost Tree Capital LLC	15,000	$1.61M	0.5%	+51.6%	0.032%
5/15/2023	Farallon Capital Management LLC	1,100,806	$118.14M	0.7%	+658.7%	2.316%
5/12/2023	Westfield Capital Management Co. LP	684,694	$73.48M	0.5%	+115.2%	1.441%
5/12/2023	Senator Investment Group LP	125,000	$13.42M	0.7%	+25.0%	0.263%
5/12/2023	Sectoral Asset Management Inc.	108,090	$11.60M	2.2%	-3.7%	0.227%
5/12/2023	Mirabella Financial Services LLP	5,198	$1.26M	0.2%	N/A	0.011%
5/12/2023	Martingale Asset Management L P	2,849	$0.31M	0.0%	N/A	0.006%
5/12/2023	Nicholas Investment Partners LP	272,910	$29.29M	2.2%	-3.6%	0.574%
5/12/2023	ProShare Advisors LLC	7,391	$0.79M	0.0%	-7.0%	0.016%
5/12/2023	Profund Advisors LLC	11,488	$1.23M	0.1%	N/A	0.024%
5/12/2023	Platinum Investment Management Ltd.	231,521	$24.85M	0.9%	-12.9%	0.487%
5/11/2023	FMR LLC	1,146,049	$122.99M	0.0%	+51.9%	2.411%
5/11/2023	American Century Companies Inc.	101,636	$10.82M	0.0%	+232.8%	0.214%
5/11/2023	Artisan Partners Limited Partnership	34,592	$3.71M	0.0%	N/A	0.073%
5/11/2023	E Fund Management Co. Ltd.	3,377	$0.36M	0.0%	-12.0%	0.007%
5/11/2023	Guggenheim Capital LLC	14,103	$1.51M	0.0%	+159.3%	0.030%
5/11/2023	Skandinaviska Enskilda Banken AB publ	9,041	$0.97M	0.0%	-4.1%	0.019%
5/10/2023	Moran Wealth Management LLC	3,320	$0.36M	0.0%	-37.3%	0.007%
5/10/2023	Bank of Hawaii	4,986	$0.54M	0.0%	+34.4%	0.010%
5/10/2023	Credit Suisse AG	19,049	$2.04M	0.0%	+12.3%	0.040%
5/10/2023	Nelson Van Denburg & Campbell Wealth Management Group LLC	3,434	$0.37M	0.0%	+100.4%	0.007%
5/10/2023	Decheng Capital Management III Cayman LLC	150,000	$16.10M	6.5%	-40.0%	0.316%
5/10/2023	Pictet Asset Management SA	251,806	$27.02M	0.0%	+8,386.9%	0.530%
5/10/2023	Swiss National Bank	50,100	$5.38M	0.0%	-10.7%	0.105%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	3,827	$0.41M	0.0%	-70.0%	0.008%
5/10/2023	Tekla Capital Management LLC	50,538	$5.42M	0.2%	+32.2%	0.106%
5/10/2023	TimesSquare Capital Management LLC	164,055	$17.61M	0.3%	N/A	0.345%
5/9/2023	Principal Financial Group Inc.	167,475	$17.97M	0.0%	+1,524.6%	0.352%
5/9/2023	Tower Research Capital LLC TRC	1,329	$0.14M	0.0%	+411.2%	0.003%
5/9/2023	Bank of New York Mellon Corp	149,996	$16.10M	0.0%	-0.8%	0.316%
5/9/2023	AR Asset Management Inc.	50,414	$5.41M	1.5%	-0.8%	0.106%
5/9/2023	Integral Health Asset Management LLC	30,000	$3.22M	0.6%	+50.0%	0.063%
5/9/2023	California State Teachers Retirement System	33,364	$3.58M	0.0%	-2.2%	0.070%
5/9/2023	Clearstead Advisors LLC	365	$39K	0.0%	N/A	0.001%
5/9/2023	Russell Investments Group Ltd.	59,697	$6.41M	0.0%	+36.7%	0.126%
5/8/2023	Public Employees Retirement Association of Colorado	3,270	$0.35M	0.0%	N/A	0.007%
5/8/2023	Federated Hermes Inc.	516,589	$55.44M	0.1%	-1.1%	1.087%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	3,792	$0.41M	0.0%	+42.9%	0.008%
5/5/2023	Truist Financial Corp	2,238	$0.24M	0.0%	-43.3%	0.005%
5/5/2023	Assetmark Inc.	379	$41K	0.0%	N/A	0.001%
5/4/2023	Barclays PLC	36,510	$3.92M	0.0%	-21.9%	0.077%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	18,604	$2M	0.0%	+15.9%	0.039%
5/4/2023	Emerald Mutual Fund Advisers Trust	104,825	$11.25M	0.7%	-13.2%	0.221%
5/4/2023	Emerald Advisers LLC	126,436	$13.57M	0.7%	-15.5%	0.266%
5/2/2023	Victory Capital Management Inc.	172,914	$18.56M	0.0%	+46.0%	0.364%
5/2/2023	Nisa Investment Advisors LLC	1,166	$0.13M	0.0%	+355.5%	0.002%
5/2/2023	Amalgamated Bank	4,917	$0.53M	0.0%	-14.1%	0.010%
5/1/2023	Virtu Financial LLC	3,949	$0.42M	0.0%	N/A	0.008%
4/28/2023	SG Americas Securities LLC	22,321	$2.40M	0.0%	+84.4%	0.047%
4/28/2023	China Universal Asset Management Co. Ltd.	644	$69K	0.0%	+51.2%	0.001%
4/27/2023	Moody Aldrich Partners LLC	12,243	$1.31M	0.3%	-3.5%	0.026%
4/27/2023	Arizona State Retirement System	6,735	$0.72M	0.0%	+2.9%	0.014%
4/27/2023	Strs Ohio	6,700	$0.72M	0.0%	+148.1%	0.014%
4/26/2023	State of New Jersey Common Pension Fund D	19,932	$2.14M	0.0%	N/A	0.042%
4/26/2023	Supplemental Annuity Collective Trust of NJ	6,000	$0.64M	0.3%	N/A	0.013%
4/26/2023	NJ State Employees Deferred Compensation Plan	15,000	$1.61M	0.2%	+275.0%	0.032%
4/26/2023	Jennison Associates LLC	122,495	$13.15M	0.0%	+0.0%	0.258%
4/26/2023	Harbor Capital Advisors Inc.	2,099	$0.23M	0.1%	N/A	0.004%
4/24/2023	Mackenzie Financial Corp	2,139	$0.23M	0.0%	-2.5%	0.005%
4/13/2023	Waypoint Capital Advisors LLC	154,466	$16.58M	5.4%	-9.8%	0.325%
4/13/2023	Allspring Global Investments Holdings LLC	1,250	$0.13M	0.0%	-9.1%	0.003%
4/11/2023	Renaissance Capital LLC	11,503	$1.24M	0.9%	N/A	0.024%
3/31/2023	Metropolitan Life Insurance Co. NY	2,160	$0.24M	0.0%	+20.5%	0.005%
3/27/2023	Neo Ivy Capital Management	7,068	$0.78M	0.5%	N/A	0.015%
3/23/2023	MetLife Investment Management LLC	18,318	$2.02M	0.0%	+4.9%	0.039%
3/10/2023	Victory Capital Management Inc.	118,407	$13.03M	0.0%	+1,359.1%	0.249%
2/28/2023	Voya Investment Management LLC	70,743	$7.78M	0.0%	+35.8%	0.169%
2/15/2023	Fred Alger Management LLC	1,359,256	$149.52M	0.8%	+31.2%	3.241%
2/15/2023	Artia Global Partners LP	22,321	$2.46M	0.9%	N/A	0.053%
2/15/2023	Avidity Partners Management LP	204,000	$22.44M	0.5%	N/A	0.486%
2/14/2023	Wexford Capital LP	4,506	$0.50M	0.1%	N/A	0.011%
2/14/2023	Point72 Asset Management L.P.	1,266,083	$139.27M	0.5%	+113.5%	3.019%
2/14/2023	Boxer Capital LLC	1,897,500	$208.73M	11.0%	+10.7%	4.524%
2/14/2023	Driehaus Capital Management LLC	271,079	$29.82M	0.4%	N/A	0.646%
2/13/2023	Moran Wealth Management LLC	5,292	$0.58M	0.0%	N/A	0.013%
2/13/2023	Platinum Investment Management Ltd.	265,791	$29.24M	1.1%	-24.8%	0.634%
2/13/2023	Gyon Technologies Capital Management LP	3,285	$0.36M	0.1%	N/A	0.008%
2/13/2023	Oversea Chinese Banking CORP Ltd	5,442	$0.60M	0.0%	N/A	0.013%
2/13/2023	Renaissance Technologies LLC	242,575	$26.68M	0.0%	+120.0%	0.578%
2/13/2023	Seven Eight Capital LP	12,627	$1.39M	0.4%	N/A	0.030%
2/13/2023	ExodusPoint Capital Management LP	58,070	$6.39M	0.1%	N/A	0.138%
2/13/2023	Geode Capital Management LLC	646,647	$71.13M	0.0%	+20.6%	1.542%
2/13/2023	GSA Capital Partners LLP	3,345	$0.37M	0.0%	-56.9%	0.008%
2/13/2023	Advisory Research Inc.	5,590	$0.62M	0.1%	-35.8%	0.013%
2/10/2023	American International Group Inc.	16,459	$1.81M	0.0%	+13.2%	0.039%
2/10/2023	Amalgamated Bank	5,727	$0.63M	0.0%	+15.7%	0.014%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	12,774	$1.41M	0.0%	N/A	0.030%
2/10/2023	Sectoral Asset Management Inc.	112,210	$12.34M	2.4%	+8.7%	0.268%
2/10/2023	Franklin Resources Inc.	461,848	$50.80M	0.0%	-12.6%	1.101%
2/10/2023	HRT Financial LP	2,806	$0.31M	0.0%	N/A	0.007%
2/10/2023	Tekla Capital Management LLC	38,237	$4.21M	0.2%	+21.4%	0.091%
2/10/2023	Lord Abbett & CO. LLC	303,058	$33.34M	0.1%	N/A	0.723%
2/9/2023	Landscape Capital Management L.L.C.	3,128	$0.34M	0.1%	N/A	0.007%

Data available starting January 2016

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Today's Range

Now: $199.92

$199.60

$199.98

50 Day Range

MA: $198.62

$192.50

$199.92

52 Week Range

Now: $199.92

$23.27

$199.98

Volume

1,860,600 shs

Average Volume

913,102 shs

Market Capitalization

$9.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Prometheus Biosciences?: Prometheus Biosciences' top insider shareholders include:
Sinai Intellectual Prop Cedars (Major Shareholder)
Mark C Mckenna (CEO)
Keith W Marshall (CFO)
Learn More about top insider investors at Prometheus Biosciences.